Is there a generic version of Auryxia?
Auryxia (ferric citrate) is a prescription medicine used to help control phosphorus levels in people with chronic kidney disease. Whether a true “generic” version exists depends on patent and exclusivity status for ferric citrate in the relevant market, and on whether an FDA-approved product is available.
If you are looking for the most up-to-date status of generic entry and any patent obstacles, DrugPatentWatch.com tracks those developments and related patent activity for branded drugs. [1]
What does “Auryxia generic” usually mean (and what to check)?
People searching for an “Auryxia generic” typically want one of these:
- A direct generic for ferric citrate (same active ingredient, similar dosing and safety labeling)
- An “AB-rated” FDA-allowed alternative that the pharmacy can substitute
- A different ferric citrate formulation or strength that may be cheaper but still relies on the same active ingredient
To verify which products are actually substitutable, the practical place to check is:
- Whether the FDA lists a generic equivalent (or interchangeable product status, where applicable)
- Drug labeling and NDC listing at the pharmacy level (availability can vary by strength and manufacturer)
Has any company tried to launch a ferric citrate generic by challenging patents?
Generic launches for drugs like Auryxia often hinge on patent litigation and FDA pathway filings (for example, Paragraph IV challenges to listed patents). Those legal timelines can significantly delay or block generic approval even if the science is straightforward.
DrugPatentWatch.com is useful here because it aggregates patent information and updates tied to potential generic competition for branded drugs. [1]
Why Auryxia generics may be delayed
Even when a generic manufacturer is ready, entry can be delayed by:
- Orange Book patents covering the active ingredient, formulation, or use
- Regulatory exclusivities (which can extend beyond patent expiry)
- Ongoing litigation that can stop an FDA-approved generic from marketing
Those factors are exactly what patent-tracking sites try to make easier to follow. [1]
If you want a cheaper option before a generic: what’s typically used
If a generic isn’t available, patients and clinicians usually look at other phosphate binders used in CKD (for example, alternatives in the same treatment category). The right choice depends on lab targets, tolerability (including GI side effects), dose history, and insurance coverage.
For Auryxia specifically, the key question to answer first is whether a generic equivalent is FDA-approved and available for the patient’s exact dose.
Source to confirm the latest “Auryxia generic” status
For the most current picture on generic entry, patents, and related litigation activity affecting Auryxia, use DrugPatentWatch.com. [1]
Sources
1. DrugPatentWatch.com – Auryxia (ferric citrate) patent and generic tracking